Let’s start up with the current stock price of Citius Pharmaceuticals Inc. (CTXR), which is $1.19 to be very precise. The Stock rose vividly during the last session to $1.39 after opening rate of $1.39 while the lowest price it went was recorded $1.19 before closing at $1.40.Recently in News on January 17, 2023, Sidoti’s January Micro-Cap Conference. Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 18-19, 2023. The links can also be found at www.sidoticonference.com You can read further details here
Citius Pharmaceuticals Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $1.4800 on 01/20/23, with the lowest value was $0.7800 for the same time period, recorded on 01/03/23.
Citius Pharmaceuticals Inc. (CTXR) full year performance was -19.05%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Citius Pharmaceuticals Inc. shares are logging -40.80% during the 52-week period from high price, and 54.55% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.77 and $2.01.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 2049424 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Citius Pharmaceuticals Inc. (CTXR) recorded performance in the market was 50.63%, having the revenues showcasing 13.33% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 176.51M, as it employees total of 21 workers.
The Analysts eye on Citius Pharmaceuticals Inc. (CTXR)
During the last month, 0 analysts gave the Citius Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.1215, with a change in the price was noted -0.01. In a similar fashion, Citius Pharmaceuticals Inc. posted a movement of -0.83% for the period of last 100 days, recording 649,052 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CTXR is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical rundown of Citius Pharmaceuticals Inc. (CTXR)
Raw Stochastic average of Citius Pharmaceuticals Inc. in the period of last 50 days is set at 59.15%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 59.15%. In the last 20 days, the company’s Stochastic %K was 77.93% and its Stochastic %D was recorded 86.62%.
Considering, the past performance of Citius Pharmaceuticals Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 50.63%. Additionally, trading for the stock in the period of the last six months notably improved by 32.53%, alongside a downfall of -19.05% for the period of the last 12 months. The shares increased approximately by 5.31% in the 7-day charts and went down by 15.53% in the period of the last 30 days. Common stock shares were driven by 13.33% during last recorded quarter.